Buchumschlag

AraC-based pharmacotherapy of chronic myeloid leukaemia

In interferon-α (IFN) treated chronic phase chronic myeloid leukaemia (CML) patients, survival depends on individual risk profile and achievement of a complete haematological response (CHR) and a major cytogenetic response (MCR) (< 35% Philadelphia-chromosome-positive metaphases). The highest cyt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reiter, Andreas (VerfasserIn) , Hochhaus, Andreas (VerfasserIn) , Berger, Ute (VerfasserIn) , Kuhn, Christian (VerfasserIn) , Hehlmann, Rüdiger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2001
In: Expert opinion on pharmacotherapy
Year: 2001, Jahrgang: 2, Heft: 7, Pages: 1129-1135
ISSN:1744-7666
DOI:10.1517/14656566.2.7.1129
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656566.2.7.1129
Volltext
Verfasserangaben:Andreas Reiter, Andreas Hochhaus, Ute Berger, Christian Kuhn & Rüdiger Hehlmann
Beschreibung
Zusammenfassung:In interferon-α (IFN) treated chronic phase chronic myeloid leukaemia (CML) patients, survival depends on individual risk profile and achievement of a complete haematological response (CHR) and a major cytogenetic response (MCR) (< 35% Philadelphia-chromosome-positive metaphases). The highest cytogenetic response rates have been achieved with the combination of IFN and low-dose sc. AraC (10 mg daily to 10 - 20 mg/m2 for 10 - 14 days/month). Whether the higher cytogenetic response rates are also associated with a significant improvement of survival still remains controversial. The different results obtained from large randomised and observational trials may be due to the numbers of patients enrolled, distribution of risk profiles and the treatment schedule, which is influenced greatly by the haematological and gastrointestinal toxicity of AraC. An oral formulation (YNK01), which is lipophilic and resistant to deamination, is currently under investigation. Clinically, it has similar activity, but toxicity leads to discontinuation of treatment in a considerable proportion of patients. The clinical benefits may therefore be outweighed by the dose-limiting toxicity for both application forms. Combinations with other drugs, e.g., STI571 or homoharringtonine, have shown promising early results in vitro and in vivo.
Beschreibung:Elektronische Reproduktion der Druckausgabe
Gesehen am 18.05.2022
Beschreibung:Online Resource
ISSN:1744-7666
DOI:10.1517/14656566.2.7.1129

Ähnliche Einträge